A personalized cancer vaccine developed by Moderna and Merck may be a triumph of immunology and cancer biology. It might also be the triumph of an algorithm. Cancer Hospitals Mental Health Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out Reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Biotech The mystery of Moderna’s magic algorithm Is it the ‘secret…
A personalized cancer vaccine developed by Moderna and Merck has generated widespread enthusiasm since the companies announced last week that it had succeeded in a late-stage trial. If regulators ultimately approve it, the treatment will be a triumph of immunology and cancer biology.
But it may also be a triumph of the algorithm.
The vaccine, intismeran autogene, would be the first approved medicine whose genetic instructions — that is, the individual letters of its mRNA — is determined by a computer.
Continue to STAT+ to read the full story…
US Pharma Marketing